Foghorn Therapeutics (Foghorn Therapeutics) Revenue per Share : $0.81 (TTM As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Foghorn Therapeutics Revenue per Share?

Foghorn Therapeutics's revenue per share for the three months ended in Mar. 2024 was $0.12. Foghorn Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.81.

During the past 12 months, the average Revenue Per Share Growth Rate of Foghorn Therapeutics was 63.20% per year. During the past 3 years, the average Revenue Per Share Growth Rate was 175.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Foghorn Therapeutics's Revenue per Share or its related term are showing as below:

FHTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 175.3 Med: 175.3 Max: 175.3
Current: 175.3

During the past 6 years, Foghorn Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was 175.30% per year. The lowest was 175.30% per year. And the median was 175.30% per year.

FHTX's 3-Year Revenue Growth Rate is ranked better than
95.51% of 779 companies
in the Biotechnology industry
Industry Median: 3.5 vs FHTX: 175.30

Foghorn Therapeutics Revenue per Share Historical Data

The historical data trend for Foghorn Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Foghorn Therapeutics Revenue per Share Chart

Foghorn Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Revenue per Share

Get a 7-Day Free Trial

0.04

0.46

0.81

Foghorn Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Revenue per Share	Get a 7-Day Free Trial															0.13	0.13	0.42	0.14	0.12

Competitive Comparison of Foghorn Therapeutics's Revenue per Share

For the Biotechnology subindustry, Foghorn Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Foghorn Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Foghorn Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Foghorn Therapeutics's PS Ratio falls into.

Foghorn Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Foghorn Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )	=	Revenue (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	34.155	/	41.974
	=	0.81

Foghorn Therapeutics's Revenue Per Share for the quarter that ended in Mar. 2024 is calculated as

Revenue Per Share (Q: Mar. 2024 )	=	Revenue (Q: Mar. 2024 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
	=	5.05	/	42.429
	=	0.12

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.81

Foghorn Therapeutics (NAS:FHTX) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Foghorn Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Foghorn Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Foghorn Therapeutics (Foghorn Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Foghorn Therapeutics Inc (NAS:FHTX) » Definitions » Revenue per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Technology Square, Suite 700, Cambridge, MA, USA, 02139

Website

https://www.foghorntx.com

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Executives

Alfonso Quintas Cardama	officer: Chief Medical Officer	C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142
Samuel Agresta	officer: Chief Medical Officer	784 MEMORIAL DR., CAMBRIDGE MA 02139
Lynch Thomas J. Jr.	director	800 HOWARD AVENUE, YALE PHYSICIANS BUILDING, 2ND FLOOR, NEW HAVEN CT 06519
B Lynne Parshall	director	2855 GAZELLE COURT, CARLSBAD CA 92010
Carlos Costa	officer: Chief People Officer	C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Fanny Cavalie	officer: Chief Strategy/Bus Ops Officer	C/O FOGHORN THERAPEUTICS INC., 500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Ian F Smith	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Michael Lacascia	officer: Chief Legal Officer	500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Carl Decicco	officer: Chief Scientific Officer	100 BINNEY STREET, SUITE 610, CAMBRIDGE MA 02142
Flagship Ventures Opportunities Fund I General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Abu Dhabi Investment Authority	10 percent owner	211 CORNICHE STREET, PO BOX 3600, ABU DHABI C0 0000
Michael Mendelsohn	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Adam Koppel	director	C/O BROOKSIDE CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON ST, BOSTON MA 02116
Steven F. Bellon	officer: See Remarks	500 TECHNOLOGY SQUARE, SUITE 700, CAMBRIDGE MA 02139
Jose Baselga	director	780 MEMORIAL DRIVE, CAMBRIDGE MA 02139